Science and Technology
Source : (remove) : STAT
RSSJSONXMLCSV
Science and Technology
Source : (remove) : STAT
RSSJSONXMLCSV
Thu, June 5, 2025
Sat, May 31, 2025
Thu, May 29, 2025
Wed, May 28, 2025
Sat, May 24, 2025
Fri, May 23, 2025
Wed, May 21, 2025
Mon, May 19, 2025
Tue, May 13, 2025
Sun, May 4, 2025
Tue, April 29, 2025
Mon, April 28, 2025
Tue, April 22, 2025
Wed, April 16, 2025
Tue, April 15, 2025
Fri, March 28, 2025
Wed, March 26, 2025
Tue, March 25, 2025
Thu, March 13, 2025
Fri, March 7, 2025
Thu, March 6, 2025
Mon, February 17, 2025
Fri, February 14, 2025
Fri, February 7, 2025
[ Fri, Feb 07th ] - STAT
Signs of life at the CDC
Tue, February 4, 2025
Tue, January 21, 2025

A cautious culture cost Novo its obesity lead


//science-technology.news-articles.net/content/2 .. cautious-culture-cost-novo-its-obesity-lead.html
Published in Science and Technology on by STAT   Print publication without navigation

And more biotech news updates, brought to you by The Readout.

The article from STAT News dated June 5, 2025, discusses several significant developments in the biotech industry. Novo Nordisk is set to acquire Vigil Neuroscience for $1.5 billion, aiming to bolster its neuroscience portfolio. Merck is facing challenges with its blockbuster cancer drug Keytruda, as a new study suggests it may not be as effective in certain patient populations as previously thought. Eli Lilly is expanding its manufacturing capabilities to meet the growing demand for its diabetes and obesity treatments. Lastly, REGENXBIO reported positive results from a Phase II trial of its gene therapy for Duchenne muscular dystrophy, sparking optimism about future treatments for the condition.

Read the Full STAT Article at:
[ https://www.statnews.com/2025/06/05/biotech-news-novo-nordisk-vigil-merck-eli-lilly-regenxbio-keytruda-the-readout/ ]

Publication Contributing Sources